Ageing in Werner syndrome

BioScience Trends

Volumn 6, Issue 1, 2012, Pages 33-37

  Goto, Makoto ^a   Iwaki Egawa, Sachiko ^b   Watanabe, Yasuhiro ^b  

^a TOIN UNIVERSITY OF YOKOHAMA   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Aging; C reactive protein (CRP); Homocysteine; Inflammation; Matrix Metalloproteinase 9 (MMP 9); Oxidative stress; Pentosidine

Indexed keywords

ARGININE; DRUG DERIVATIVE; HOMOCYSTEINE; LYSINE; PENTOSIDINE;

ADULT; AGED; AGING; ARTICLE; BLOOD; FEMALE; HEALTH; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; WERNER SYNDROME;

ADULT; AGED, 80 AND OVER; AGING; ARGININE; FEMALE; HEALTH; HOMOCYSTEINE; HUMANS; LYSINE; MALE; MIDDLE AGED; WERNER SYNDROME;

EID: 84862218594     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.1.33     Document Type: Article

References (46)

1. Goto M. Inflammaging (inflammation + aging): A driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2008; 2:218-230.
2. Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol. 2009; 5:208-217.
3. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion: Effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol. 2002; 22:772-780.
4. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009; 11:R39.
5. Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Emoto M, Tahara H, Inaba M, Kakiya R, Tabata T, Miyata T, Nishizawa Y. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism. 2011; 60:453-459.
6. Halliwell B, Hoult JR, Blake DR. Oxidants, inflammation, and anti-inflammatory drugs. FASEB J. 1988; 2:2867-2873.
7. Taneda S, Monnier VM. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem. 1994; 40:1766-1773.
8. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest. 1990; 85:380-384.
9. Baynes JW. The role of AGEs in aging: Causation or correlation. Exp Gerontol. 2001; 36:1527-1537.
10. Baynes JW. The Maillard hypothesis on aging: Time to focus on DNA. Ann N Y Acad Sci. 2002; 959:360-367.
11. Monnier VM, Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science. 1981; 211:491-493.
12. Brownlee M, Vlassara H, Cerami A. Nonenzymatic g l y c a t i o n and t h e pathogenesis o f d i a b t e t i c complications. Ann Intern Med. 1984; 101:527-537.
13. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Rec Prog Horm Res. 2001; 56:1-21.
14. Harja E, Hudson BI, Chang JS, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008; 118:183-194.
15. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Comm. 1998; 244:45-49.
16. Steenvoorden MM, Huizinga TW, Verzijl N, Bank RA, Ronday HK, Luning HA, Lafeber FPJG, Toes RE, DeGroot J. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum. 2006; 54:253-263.
17. Suliman ME, Heimbürger O, Bárány P, Anderstam B, Pecoits-Filho R, Rodríguez Ayala E, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003; 14:1614-1622.
18. Kitauchi T, Yosida K, Yoneda T, Saka T, Yoshikawa M, Ozono S, Hirao Y. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol. 2004; 8:48-53.
19. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000; 908:244-254.
20. Jacob RA, Burri BJ. Oxidative damage and defense. Am J Clin Nutr. 1996; 63:985S-990S.
21. Hajjar KA. Homocysteine: A sulph'rous fire. J Clin Invest. 2001; 107:663-664.
22. Sibrian-Vazquez M, Escobedo JO, Lim S, Samoei GK, Strongin RM. Homocystamides promote free-radical and oxidative damage to proteins. Proc Natl Acad Sci U S A. 2010; 107:551-554.
23. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001; 107:675-683.
24. Collins T, Cybulsky MI. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001; 107:255-264.
25. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW. Nonfasting plasma total homocysteine levels and allcause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999; 159:1077-1080.
26. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study. BMJ. 2009; 338: a3083.
27. Kado DM, Bucur A, Selhub J, Rowe JW, Seeman T. Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. Am J Med. 2002; 113:537-542.
28. Glushchenko AV, Jacobsen DW. Molecular targeting of proteins by L-homocysteine: Mechanistic implications for vascular disease. Antioxid Redox Signal. 2007; 9:1883-1898.
29. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274:1049-1057.
30. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004; 109 (Suppl 1):IV6-IV19.
31. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of food supply. Potential benefits and risks for elderly population. JAMA. 1996; 276:1879-1885.
32. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ. 1998; 316:894-898.
33. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998; 338:1009-1015.
34. Watanabe T, Suemura K, Taniguchi A, Ebara S, Kimura S, Fukui T. Dietary intake of seven B vitamins based on a total diet study in Japan. J Nutr Sci Vitaminol. 2010; 56:279-286.
35. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA. 2006; 296:2720-2726.
36. Joseph J, Handy DE, Loscalzo J. Quo vadis: Whither homocysteine research? Cardiovasc Toxicol. 2009; 9:53-63.
37. Goto M, Miller RW. From premature gray hair to helicase-Werner syndrome: Implications for aging and cancer. In: Monograph on Cancer Research. No.49, Japan Scientific Societies Press & Karger, Tokyo, Japan, 2001.
38. Goto M. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol. 2010; 20:238-243.
39. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987; 422:43-52.
40. Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron. 2002; 91:64-73.
41. Fujimoto N, Hosokawa N, Iwata K, Shinya T, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta. 1994; 231:79-88.
42. Tyagi N, Gillespie W, Vacek JC, Sen U, Tyagi SC, Lominadze D. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol. 2009; 220:257-266.
43. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005; 15:16R-28R.
44. Zhang C, Hu JJ, Xia M, Boini KM, Brimson C, Li PL. Redox signaling via lipid raft clustering in homocysteineinduced injury of podocytes. Biochim Biophys Acta. 2010; 1803:482-491.
45. Jacobsen DW. Hyperhomocysteinemia and oxidative stress: Time for a reality check? Arterioscler Thrombo Vasc Biol. 2000; 20:1182-1184.
46. Pagano G, Zatterale A, Degan P, d'Ischia M, Kelly FJ, Pallardó FV, Kodama S. Multiple involvement of oxidative stress in Werner syndrome phenotype. Biogerontology. 2005; 6:233-243.